PRMT7-Related Short Stature–Brachydactyly Syndrome: Research Report

Executive summary

PRMT7-related short stature–brachydactyly syndrome is an ultra-rare autosomal-recessive neurodevelopmental disorder caused by biallelic variants in PRMT7. It is commonly called SBIDDS—short stature, brachydactyly, intellectual developmental disability, and seizures—and is also described as PRMT7-related disorder or short stature, brachydactyly, intellectual developmental disability, and seizures syndrome. The defining clinical combination is developmental delay/intellectual disability, hypotonia, short stature, brachydactyly/metacarpal-metatarsal shortening, characteristic craniofacial morphology, variably occurring seizures, and frequently later-onset obesity.

The best current clinical evidence is the January 2023 Genetics in Medicine study of 51 affected people from 39 families. This remains a small, largely cross-sectional cohort rather than a population-based natural-history study; therefore, percentages below should be interpreted as observed cohort frequencies, not definitive penetrance estimates. (cali2023biallelicprmt7pathogenic pages 2-5, cali2023biallelicprmt7pathogenic pages 1-2)

Table: This table summarizes the strongest currently available evidence for PRMT7-related SBIDDS, centered on the 2023 51-person cohort and supported by mechanistic model data. It is useful for rapid knowledge-base population because it combines phenotype frequencies, inheritance and variant classes, diagnostics, management, and explicit evidence gaps in one place.

1. Disease information

Definition and identifiers

• Disease: Mendelian syndromic neurodevelopmental disorder caused by biallelic PRMT7 variants.
• OMIM phenotype: 617157.
• Causal gene: PRMT7, OMIM 610087.
• Inheritance: Autosomal recessive.
• Common names: SBIDDS; PRMT7-related disorder; PRMT7-related short stature–brachydactyly syndrome; short stature, brachydactyly, intellectual developmental disability, and seizures syndrome.
• MONDO: A stable MONDO identifier was not established from the retrieved authoritative evidence; it should not be inferred from the OMIM number.
• Orphanet, MeSH, ICD-10/ICD-11: No disease-specific identifiers were established in the retrieved evidence. In practice, broader codes for genetic neurodevelopmental disorder, intellectual disability, epilepsy, short stature, or congenital malformations may be used, but these are not equivalent to a disease-specific code.

The 2023 paper describes the condition as a “recognizable syndromic neurodevelopmental disorder with short stature, obesity, and craniofacial and digital abnormalities.” It combined 36 newly described individuals with 15 previously reported individuals. DOI: 10.1016/j.gim.2022.09.016, published January 2023. (cali2023biallelicprmt7pathogenic pages 1-2)

The evidence is principally aggregated disease-level research assembled from individually phenotyped patients and literature cases, not an EHR-derived population dataset. Photographs, clinical records, sequencing results, and segregation studies contributed to the cohort characterization. (cali2023biallelicprmt7pathogenic pages 2-5)

2. Etiology, risk, and protective factors

The primary and presently sufficient cause is germline biallelic variation in PRMT7. The cohort contained 25 compound-heterozygous and 26 homozygous individuals, supporting a recessive disease model. Consanguinity was recorded in 44% of families, increasing the probability of homozygosity but not constituting an independent biological cause. (cali2023biallelicprmt7pathogenic pages 2-5)

No reproducible susceptibility loci, modifier genes, genetic protective alleles, environmental causes, toxins, infections, dietary factors, or gene–environment interactions have been demonstrated for SBIDDS. Sex is not an established human risk modifier: the largest cohort included 23 males and 28 females. Family history and parental relatedness affect recurrence probability rather than severity in a proven manner. (cali2023biallelicprmt7pathogenic pages 2-5)

Environmental and lifestyle factors may modify secondary obesity, fitness, or bone health in the same general way they do in other patients, but there is no evidence that they cause or prevent the syndrome. The female-specific skeletal phenotype reported in a 2024 conditional-mouse study is hypothesis-generating and cannot yet be treated as evidence of sex-specific human penetrance. (zhang2024prmt7mediatedpten pages 4-7)

3. Phenotypes and quality-of-life implications

Neurodevelopment

Global developmental delay or intellectual disability occurred in 100% of the 2023 cohort: 27% mild, 33% moderate, and 40% severe. Hypotonia occurred in approximately 88%. These congenital/early-childhood manifestations are chronic rather than episodic and commonly affect mobility, communication, learning, independence, and educational needs. Suggested HPO terms are Global developmental delay (HP:0001263), Intellectual disability (HP:0001249), and Hypotonia (HP:0001252). (cali2023biallelicprmt7pathogenic pages 1-2)

Seizures and brain findings

Approximately 67–70% developed seizures. Median onset was three years, with a wide reported range of seven months to 45 years. Generalized-onset seizures predominated among characterized cases, although focal seizures also occurred. Most responded to treatment; approximately 16% were intractable. Suggested term: Seizure (HP:0001250). (cali2023biallelicprmt7pathogenic pages 2-5, cali2023biallelicprmt7pathogenic pages 1-2)

MRI is not diagnostic: 13 of 37 reported scans were unremarkable, while other patients had heterogeneous, nonspecific findings such as ventricular enlargement or white-matter abnormalities. A normal MRI therefore does not exclude the disorder. (cali2023biallelicprmt7pathogenic pages 2-5)

Growth, skeleton, and digits

Short stature occurred in approximately 80%, and brachydactyly in approximately 70%. Hand/foot radiographs may show shortened metacarpals or metatarsals. Delayed bone age was reported in about 50% and decreased bone density in about 40% of assessed patients. Suggested terms include Short stature (HP:0004322), Brachydactyly (HP:0001156), Delayed bone age (HP:0002750), and decreased bone mineral density. (cali2023biallelicprmt7pathogenic pages 2-5, cali2023biallelicprmt7pathogenic pages 5-6, cali2023biallelicprmt7pathogenic pages 1-2)

Prenatal growth disturbance is frequent but not universal: roughly 45–55% had intrauterine growth restriction or other prenatal manifestations, and approximately 46–50% were small for gestational age. Suggested terms: Intrauterine growth retardation (HP:0001511) and Small for gestational age (HP:0001518). (cali2023biallelicprmt7pathogenic pages 2-5, cali2023biallelicprmt7pathogenic pages 5-6)

Obesity and muscle-related manifestations

Obesity occurred in approximately 50–54% and was more prevalent after age ten or after puberty, suggesting an age-dependent phenotype rather than a universal congenital feature. Some patients had reduced exercise endurance. Suggested term: Obesity (HP:0001513). (cali2023biallelicprmt7pathogenic pages 5-6, cali2023biallelicprmt7pathogenic pages 1-2)

Craniofacial, ophthalmic, auditory, and other findings

The recognizable gestalt includes bifrontal narrowing or frontal bossing, prominent supraorbital ridges, sparse eyebrows, a short nose with broad tip, thin upper lip, full/everted lower lip, and prominent or squared jaw/chin. Reported frequencies included frontal bossing around 70%, prognathism 72.5%, and tall/prominent chin 75%. Strabismus occurred in approximately 45%, hearing impairment in 30%, microcephaly in 40%, and failure to thrive in 51%. Suggested terms include Frontal bossing (HP:0002007), Prognathism (HP:0000303), Strabismus (HP:0000486), Hearing impairment (HP:0000365), and Microcephaly (HP:0000252). (cali2023biallelicprmt7pathogenic pages 2-5, cali2023biallelicprmt7pathogenic pages 1-2)

No disease-specific EQ-5D, SF-36, PROMIS, caregiver-burden, or other formal quality-of-life study was identified. Functional burden is inferred from intellectual disability, seizures, hypotonia, reduced endurance, sensory impairment, short stature, and obesity—not quantified by validated instruments. (cali2023biallelicprmt7pathogenic pages 2-5)

4. Genetic and molecular information

PRMT7 encodes protein arginine methyltransferase 7. The 2023 cohort reported 46 variants, 34 novel: 19 truncating variants (nine frameshift and ten nonsense), nine splice variants, 14 missense variants, one in-frame deletion, and three large indels. Reported classifications were 28 pathogenic, three likely pathogenic, and 12 variants of uncertain significance; interpretation of a VUS requires segregation, phenotype, population, and functional evidence and should not be treated as diagnostic by itself. (cali2023biallelicprmt7pathogenic pages 2-5)

The broad distribution of nonsense, frameshift, splice-disrupting, and deletion alleles supports loss of function as the predominant mechanism. Disease-associated variants are germline; no somatic disease mechanism is established. The retrieved main-text evidence did not expose a reliable complete HGVS-level variant list or variant-specific gnomAD frequencies, so these should be imported directly from the paper’s supplement and ClinVar rather than reconstructed. No validated modifier gene, founder allele, recurrent protective allele, chromosomal rearrangement syndrome, anticipation, or established germline-mosaicism rate has been reported. (cali2023biallelicprmt7pathogenic pages 2-5, cali2023biallelicprmt7pathogenic pages 5-6)

PRMT7 regulates both histone and nonhistone substrates. It is generally characterized as the mammalian type III PRMT catalyzing arginine monomethylation, although older literature reports context-dependent symmetric dimethyl marks. Known experimental substrates or pathways include histones, HSP70, RNA-binding proteins, NALCN, p38-MAPK/eIF2α-related stress biology, and chromatin regulators. Exact disease-relevant substrates in human developing brain, growth plate, and digits remain unresolved. (halabelian2021structureandfunction pages 8-9, halabelian2021structureandfunction pages 6-8, halabelian2021structureandfunction pages 5-6)

5. Environmental information

No toxin, radiation exposure, pollutant, occupation, smoking, alcohol, diet, exercise pattern, or infectious agent is known to initiate SBIDDS. It is not infectious or transmissible. Lifestyle management may influence obesity, mobility, cardiovascular risk, or bone density after diagnosis but cannot correct the underlying biallelic genotype. No SBIDDS-specific CTD-type chemical association or infectious trigger was supported by the retrieved literature.

6. Mechanism and pathophysiology

Evidence-calibrated causal model

The most defensible upstream chain is:

biallelic PRMT7 loss-of-function → reduced or altered protein-arginine methylation and chromatin/nonhistone regulation → tissue-specific disturbances of developmental gene expression, neuronal excitability, muscle metabolism, adipogenesis, and osteogenesis → developmental disability/seizures, hypotonia/reduced endurance, later obesity, short stature, low bone density, and digital abnormalities.

The first link is firmly supported by human genetics; most intermediate links derive from cell and animal models and are not yet validated molecular biomarkers in patients. (cali2023biallelicprmt7pathogenic pages 2-5)

Neuronal mechanisms

PRMT7 has experimental links to neuronal development through MLL4/Wnt-related chromatin regulation and to excitability through ion-channel regulation. In mouse dentate granule neurons, PRMT7 methylation of NALCN at Arg1653 promotes inhibitory phosphorylation; deficiency increases firing through enhanced NALCN signaling. These observations provide plausible mechanisms for seizures and neurodevelopmental impairment but do not establish that NALCN dysregulation is the sole human disease mechanism. Suggested terms: GO regulation of neuron excitability, GO nervous system development; cell terms neuron, dentate granule cell, and hippocampal pyramidal neuron. (halabelian2021structureandfunction pages 8-9, cali2023biallelicprmt7pathogenic pages 2-5)

Muscle, adipose, and metabolism

Whole-body Prmt7-deficient mice exhibit impaired muscle regeneration, loss of the PAX7-positive satellite-cell pool, reduced oxidative metabolism/PGC-1α expression, altered fiber composition, and age-associated obesity. PRMT7 loss also promotes adipogenesis through C/EBP-β/PPAR-γ-related regulation. These findings align with human hypotonia, reduced endurance, and delayed obesity, but patient muscle transcriptomic or metabolomic confirmation is unavailable. Suggested terms: GO muscle cell differentiation, GO skeletal muscle tissue regeneration, GO oxidative phosphorylation, GO adipocyte differentiation; cells skeletal muscle satellite cell, myoblast, myofiber, and adipocyte. (halabelian2021structureandfunction pages 8-9, halabelian2021structureandfunction pages 12-13, halabelian2021structureandfunction pages 6-8)

Bone and craniofacial mechanisms—2024 development

Prmt7-knockout mice show reduced body size, shortened fifth metatarsals, and reduced bone mineral content, reproducing key aspects of human growth and digital disease. (halabelian2021structureandfunction pages 8-9)

A July 31, 2024 bioRxiv preprint reported that PRMT7 promotes osteogenesis through PTEN: H3R2me1 enrichment at the PTEN promoter enhanced transcription, while a separate methyltransferase-independent effect stabilized nuclear PTEN. Conditional loss in Prrx1- or Sp7-lineage cells caused female-specific dwarfism by six weeks, impaired long-bone formation/regeneration, reduced trabecular bone and mineral density, and craniofacial/dental abnormalities; PRMT7 deficiency reduced alkaline-phosphatase activity and RUNX2 expression in mouse and human bone-marrow mesenchymal stem cells. DOI: 10.1101/2024.07.31.605998. Because this is preprint/model evidence and sex specificity has not been established in patients, it should be annotated as provisional. Suggested terms: GO ossification, GO osteoblast differentiation, GO bone development; cells bone-marrow mesenchymal stem cell and osteoblast. (zhang2024prmt7mediatedpten pages 4-7)

Other tissue mechanisms

Experimental Prmt7 loss can disrupt alveolar myofibroblast proliferation/differentiation and FOXM1-associated alveologenesis, and cardiomyocyte deletion can produce hypertrophy/fibrosis through β-catenin dysregulation. These are tissue-specific mouse findings, not established routine manifestations of human SBIDDS, and should not be converted into human phenotype assertions without clinical evidence.

No SBIDDS patient-level single-cell atlas, spatial transcriptomic study, proteomic signature, metabolomic/lipidomic biomarker, integrated multi-omics study, organoid model, or disease-focused CRISPR screen was identified. The available molecular profiling is predominantly bulk transcriptomic or targeted biochemical work in experimental systems.

7. Anatomical structures affected

The primary clinically affected systems are the central nervous system, skeleton/growth apparatus, digits, craniofacial complex, skeletal muscle, and adipose/metabolic system. Secondary/recurrent involvement includes eyes and auditory pathways. Suggested anatomical annotations include brain, cerebral white matter, skeletal system, long bone, metacarpal bone, metatarsal bone, hand digit, foot digit, craniofacial skeleton, skeletal muscle, and adipose tissue; exact UBERON identifiers should be ontology-validated during ingestion rather than guessed.

At cell level, plausible affected populations are neurons, neural progenitors, skeletal-muscle satellite cells/myoblasts, adipocytes and precursors, bone-marrow mesenchymal stromal cells, osteoblast-lineage cells, and growth-plate chondrocytes. Direct patient evidence is strongest for organ-level phenotype; cell assignments are largely mechanistic extrapolations from models. (halabelian2021structureandfunction pages 8-9, zhang2024prmt7mediatedpten pages 4-7, cali2023biallelicprmt7pathogenic pages 2-5)

At subcellular level, PRMT7 acts in the nucleus/chromatin and cytoplasmic protein/RNA complexes. Suggested GO cellular components include nucleus, chromatin, cytoplasm, and protein-containing complex. Lateralization is not characteristic: short stature, brachydactyly, and craniofacial findings are generally systemic/bilateral rather than consistently unilateral.

8. Temporal development

The condition is congenital and lifelong, although different components emerge at different ages. Prenatal growth restriction may be detectable before birth. Hypotonia and developmental delay usually become evident in infancy or early childhood. Short stature and brachydactyly become clearer with growth; seizures have highly variable onset, including rare adult onset. Obesity is frequently delayed until later childhood, adolescence, or after puberty. (cali2023biallelicprmt7pathogenic pages 2-5, cali2023biallelicprmt7pathogenic pages 1-2)

There is no validated staging system. The course is best understood as chronic neurodevelopmental disability with age-dependent emergence of seizures, skeletal findings, and obesity, rather than relapsing-remitting disease. Seizures may remit or become controlled with medication, but genetic and developmental manifestations do not spontaneously resolve. Critical practical periods include early developmental intervention, early seizure recognition, longitudinal growth/bone surveillance, and anticipatory weight management before adolescence.

9. Inheritance and population

Inheritance is autosomal recessive. For two confirmed heterozygous parents, each pregnancy has a 25% probability of an affected child, 50% probability of an unaffected carrier, and 25% probability of inheriting neither familial allele, assuming conventional Mendelian segregation. The observed 44% consanguinity is consistent with enrichment of homozygous rare alleles. (cali2023biallelicprmt7pathogenic pages 2-5)

The cohort’s 23:28 male:female distribution does not suggest a major sex bias. Patients were recruited internationally, including Europe, North America, the Middle East, and Iran; this reflects ascertainment rather than measured geographic prevalence. No population-based prevalence, incidence, carrier frequency, penetrance estimate, founder effect, ethnic-risk estimate, or geographic variant-frequency map is available. The observation of 51 recognized individuals must not be interpreted as worldwide prevalence. (cali2023biallelicprmt7pathogenic pages 2-5, cali2023biallelicprmt7pathogenic pages 7-8)

Expressivity is variable, particularly for ID severity, seizures, obesity, microcephaly, and MRI findings. Anticipation is not expected and has not been reported. Germline mosaicism remains theoretically possible for most Mendelian disorders but has no quantified disease-specific rate.

10. Diagnostics

Clinical evaluation

Clinical suspicion should arise from developmental delay/ID plus hypotonia, short stature, brachydactyly or shortened metacarpals/metatarsals, characteristic facial morphology, seizures, and later-onset obesity. Recommended baseline characterization is phenotype-driven rather than based on formal diagnostic criteria:

1. Detailed developmental, neurologic, growth, and three-generation family history.
2. Physical and dysmorphology assessment, including hands and feet.
3. Height, weight/BMI, head circumference, and longitudinal growth trajectory.
4. Hand/foot or bone-age radiography when clinically indicated; consider bone-density assessment where low density or fractures are suspected.
5. EEG for suspected seizures and MRI according to neurologic indications; neither EEG nor MRI is disease-specific.
6. Hearing and ophthalmologic assessment because hearing impairment and strabismus recur.

No diagnostic enzyme assay, blood metabolite, protein biomarker, histopathology pattern, ECG, EMG, or liquid-biopsy test is validated. Routine endocrine or metabolic testing is useful to exclude alternative causes of growth failure or obesity, not to confirm SBIDDS.

Molecular confirmation

The preferred test is a neurodevelopmental-disorder, epilepsy, syndromic-short-stature, skeletal-dysplasia, or syndromic-obesity panel containing PRMT7, or trio whole-exome/whole-genome sequencing. Candidate variants should be confirmed and phased/segregated, conventionally by Sanger sequencing; this was used in the major cohort. WGS may improve detection of noncoding, copy-number, or structural variants, while exome sequencing has already demonstrated substantial utility. (cali2023biallelicprmt7pathogenic pages 2-5, cali2023biallelicprmt7pathogenic pages 1-2)

Single-gene sequencing is reasonable when the phenotype is highly characteristic and should include deletion/duplication analysis. CMA may detect large deletions but will miss most sequence variants. Karyotyping and FISH are low-yield unless another cytogenetic disorder is suspected. Mitochondrial, repeat-expansion, and somatic testing are not routine. RNA sequencing may help resolve a suspected splice variant but is not a validated first-line assay.

Differential diagnosis

Important alternatives include Börjeson–Forssman–Lehmann syndrome, CHOPS syndrome, Chung–Jansen syndrome, Cohen syndrome, TRAPPC9-related intellectual disability/obesity, pseudohypoparathyroidism/Albright hereditary osteodystrophy-like conditions, and other syndromic obesity or brachydactyly-ID disorders. Molecular testing is important because the phenotypic overlap is substantial. (halabelian2021structureandfunction pages 8-9, cali2023biallelicprmt7pathogenic pages 5-6)

No population or newborn screening program exists. Cascade testing of adult relatives and targeted testing of at-risk siblings are appropriate after familial variants are established.

11. Outcome and prognosis

No survival curve, five- or ten-year survival rate, disease-specific mortality rate, or life-expectancy estimate is available. The oldest person in the 2023 cohort was 55 years old, demonstrating survival into later adulthood but not proving normal life expectancy. (cali2023biallelicprmt7pathogenic pages 2-5)

Morbidity is chiefly neurodevelopmental and functional: persistent cognitive impairment, hypotonia, seizures, sensory problems, skeletal/growth abnormalities, and obesity. Most reported seizures were medication-responsive, while roughly 16% were intractable. The broad ID-severity distribution and heterogeneous MRI findings demonstrate variable expressivity. (cali2023biallelicprmt7pathogenic pages 2-5, cali2023biallelicprmt7pathogenic pages 1-2)

No validated prognostic biomarker exists. Likely clinical prognostic factors—ID severity, seizure control, mobility, swallowing/nutritional status, obesity, and bone health—are reasonable for care planning but have not been validated in longitudinal models. Recovery of the underlying syndrome is not expected; functional improvement through seizure control, therapy, communication support, education, and management of secondary complications is plausible but unquantified.

12. Treatment and current implementation

There is no approved PRMT7-restoring or disease-modifying therapy and no disease-specific treatment algorithm supported by trials. Current real-world implementation consists of molecular diagnosis, genetic counseling, developmental services, and organ-directed surveillance. The major cohort reported that most seizures responded to agents including topiramate or sodium valproate, although treatment must follow seizure type, age, sex/reproductive considerations, comorbidity, and local epilepsy guidance. (cali2023biallelicprmt7pathogenic pages 2-5, cali2023biallelicprmt7pathogenic pages 1-2)

A practical multidisciplinary strategy includes:

• standard antiseizure therapy and rescue planning;
• early physical, occupational, speech/language, feeding, and behavioral therapies;
• individualized education and augmentative communication where needed;
• periodic hearing and ophthalmologic evaluation;
• growth, nutrition, BMI, and metabolic-risk surveillance;
• bone-health assessment, adequate calcium/vitamin D according to general guidelines, and orthopedic/endocrine referral when indicated;
• mobility, endurance, and fall-risk support;
• psychosocial and caregiver support.

Suggested NCIT intervention labels include Anticonvulsant Therapy, Physical Therapy, Occupational Therapy, Speech Therapy, Nutritional Counseling, and Genetic Counseling. No PRMT7-directed gene therapy, CRISPR treatment, RNA therapy, cell therapy, immunotherapy, or validated targeted small molecule has entered disease-specific clinical practice. PRMT7 inhibitors studied in cancer would be mechanistically inappropriate as replacement therapy for a loss-of-function syndrome and could theoretically worsen deficient activity.

The ClinicalTrials.gov-oriented search found no relevant SBIDDS/PRMT7 interventional study; an obesity exercise trial returned by broad text matching was not disease-specific and should not be linked to this syndrome. Treatment-response rates beyond seizure-control observations and systematic adverse-event data are unavailable.

13. Prevention

Primary prevention through vaccination, lifestyle, exposure reduction, or medication is not applicable to occurrence of this inherited disorder. Reproductive prevention options after identifying familial pathogenic variants include genetic counseling, carrier testing of relatives, prenatal diagnosis, and preimplantation genetic testing for monogenic disease. Testing decisions require informed consent and local ethical/legal practice.

Secondary prevention consists of early molecular diagnosis and anticipatory surveillance—not population screening. Tertiary prevention aims to reduce complications through seizure control, developmental therapies, hearing/vision care, mobility and bone support, and early obesity management. Routine immunization remains appropriate but does not specifically prevent SBIDDS. No prophylactic medication is disease-specific.

14. Other species and natural disease

No naturally occurring PRMT7-related SBIDDS analogue in a companion-animal breed or wildlife population was identified. Accordingly, there is no evidence of veterinary transmission, zoonotic potential, or cross-species contagion. Orthologous PRMT7 genes are evolutionarily conserved in common experimental species, including mouse and zebrafish, permitting comparative functional studies. Precise NCBI Taxonomy/Gene and VBO identifiers should be obtained directly from the relevant databases during structured curation.

15. Model organisms

Mouse

Whole-body Prmt7 knockout is the principal disease-relevant model. Reported phenotypes include subviability in some strain backgrounds, reduced body size, shortened fifth metatarsals, lower bone mineral content, impaired muscle regeneration, satellite-cell depletion, reduced oxidative metabolism, altered muscle-fiber composition, and age-related obesity. It recapitulates growth, digital/skeletal, muscle, and obesity features, but does not fully model the spectrum or frequencies of human ID, seizures, facial gestalt, and sensory findings. (halabelian2021structureandfunction pages 8-9)

Conditional mouse models dissect tissue-specific biology. Neuronal experiments support altered NALCN-dependent excitability. Prrx1-Cre and Sp7-Cre skeletal-lineage knockout models support defective osteogenesis, but the 2024 female-specific phenotype remains preprint evidence. Cardiomyocyte- and lung-myofibroblast-focused models show broader PRMT7 physiology but do not establish cardiac or pulmonary SBIDDS manifestations. (halabelian2021structureandfunction pages 8-9, zhang2024prmt7mediatedpten pages 4-7)

Cellular and in-vitro models

C2C12 muscle cells, primary myofibroblasts, mouse and human bone-marrow mesenchymal cells, neuronal preparations, and other engineered cell systems have been used to study chromatin marks, senescence, myogenesis, stress responses, osteogenesis, and substrate methylation. PRMT7 knockdown in muscle cells alters Dnmt3b/Cdkn1a regulation and promotes premature senescence; HSP70 methylation supports stress-associated substrate refolding. These models are useful for pathway dissection and therapeutic screening but do not reproduce whole-patient development. (halabelian2021structureandfunction pages 8-9, zhang2024prmt7mediatedpten pages 4-7, halabelian2021structureandfunction pages 5-6)

Zebrafish and other systems

Zebrafish studies support conserved roles in antiviral/RIG-I-associated biology, but this is peripheral to the defining human phenotype. No robust SBIDDS patient-derived iPSC, cerebral organoid, growth-plate organoid, or humanized knock-in platform was identified. Appropriate model resources include MGI, IMPC, KOMP, IMSR/MMRRC, ZFIN, and Cellosaurus, with model identity and allele details verified at retrieval.

Evidence gaps and research priorities

1. A prospective international registry with standardized HPO phenotyping and longitudinal growth, seizure, obesity, bone-density, developmental, and quality-of-life outcomes.
2. Variant-level functional assessment, particularly for missense and splice VUS, with ClinVar deposition and population frequencies.
3. Patient-derived neuronal, myogenic, adipogenic, and osteogenic models to connect PRMT7 substrates to human phenotypes.
4. Patient transcriptomic/proteomic/methyl-proteomic biomarkers and studies of genotype–phenotype correlation.
5. Formal natural-history endpoints suitable for future therapeutic trials.
6. Validation of the 2024 PTEN/osteogenesis mechanism in peer-reviewed work and human tissue, including whether its reported sex effect is biologically relevant to patients. (zhang2024prmt7mediatedpten pages 4-7, cali2023biallelicprmt7pathogenic pages 2-5, cali2023biallelicprmt7pathogenic pages 6-7)

Key references

• Cali E, et al. “Biallelic PRMT7 pathogenic variants are associated with a recognizable syndromic neurodevelopmental disorder with short stature, obesity, and craniofacial and digital abnormalities.” Genetics in Medicine. Published January 2023;25:135–142. DOI: 10.1016/j.gim.2022.09.016. This is the definitive 51-person human cohort. A PMID was not exposed in the retrieved record and is therefore not guessed. (cali2023biallelicprmt7pathogenic pages 2-5, cali2023biallelicprmt7pathogenic pages 1-2)
• Halabelian L, Barsyte-Lovejoy D. “Structure and Function of Protein Arginine Methyltransferase PRMT7.” Life. Published July 2021;11:768. DOI: 10.3390/life11080768. Review integrating enzyme structure, substrates, and model phenotypes. (halabelian2021structureandfunction pages 8-9, halabelian2021structureandfunction pages 12-13)
• Zhang Y, et al. “PRMT7 mediated PTEN activation promotes bone formation in female mice.” bioRxiv preprint, posted July 2024. DOI: 10.1101/2024.07.31.605998. This is recent but not equivalent to peer-reviewed human evidence. (zhang2024prmt7mediatedpten pages 4-7)

Evidence limitation: Exact abstract quotations were only available indirectly in the retrieved records. To avoid fabricating quotation marks or PMIDs, this report quotes only the verified 2023 title phrase and otherwise paraphrases the evidence. Individual HGVS variants, database-specific ClinVar accessions, allele frequencies, and uncertain ontology IDs require direct database/supplemental-table verification before knowledge-base ingestion.

References

1. (cali2023biallelicprmt7pathogenic pages 2-5): Elisa Cali, Mohnish Suri, Marcello Scala, Matteo P. Ferla, Shahryar Alavi, Eissa Ali Faqeih, Emilia K. Bijlsma, Kristen M. Wigby, Diana Baralle, Mohammad Y.V. Mehrjardi, Jennifer Schwab, Konrad Platzer, Katharina Steindl, Mais Hashem, Marilyn Jones, Dmitriy M. Niyazov, Jennifer Jacober, Rebecca Okashah Littlejohn, Denisa Weis, Neda Zadeh, Lance Rodan, Alice Goldenberg, François Lecoquierre, Marina Dutra-Clarke, Gabriella Horvath, Dana Young, Naama Orenstein, Shahad Bawazeer, Anneke T. Vulto-van Silfhout, Yvan Herenger, Mohammadreza Dehghani, Seyed Mohammad Seyedhassani, Amir Bahreini, Mahya E. Nasab, A. Gulhan Ercan-Sencicek, Zahra Firoozfar, Mojtaba Movahedinia, Stephanie Efthymiou, Pasquale Striano, Ehsan Ghayoor Karimiani, Vincenzo Salpietro, Jenny C. Taylor, Melody Redman, Alexander P.A. Stegmann, Andreas Laner, Ghada Abdel-Salam, Megan Li, Mario Bengala, Amelie Johanna Müller, Maria C. Digilio, Anita Rauch, Murat Gunel, Hannah Titheradge, Daniela N. Schweitzer, Alison Kraus, Irene Valenzuela, Scott D. McLean, Chanika Phornphutkul, Mustafa Salih, Amber Begtrup, Rhonda E. Schnur, Erin Torti, Tobias B. Haack, Carlos E. Prada, Fowzan S. Alkuraya, Henry Houlden, and Reza Maroofian. Biallelic prmt7 pathogenic variants are associated with a recognizable syndromic neurodevelopmental disorder with short stature, obesity, and craniofacial and digital abnormalities. Genetics in Medicine, 25:135-142, Jan 2023. URL: https://doi.org/10.1016/j.gim.2022.09.016, doi:10.1016/j.gim.2022.09.016. This article has 13 citations and is from a highest quality peer-reviewed journal.

2. (cali2023biallelicprmt7pathogenic pages 1-2): Elisa Cali, Mohnish Suri, Marcello Scala, Matteo P. Ferla, Shahryar Alavi, Eissa Ali Faqeih, Emilia K. Bijlsma, Kristen M. Wigby, Diana Baralle, Mohammad Y.V. Mehrjardi, Jennifer Schwab, Konrad Platzer, Katharina Steindl, Mais Hashem, Marilyn Jones, Dmitriy M. Niyazov, Jennifer Jacober, Rebecca Okashah Littlejohn, Denisa Weis, Neda Zadeh, Lance Rodan, Alice Goldenberg, François Lecoquierre, Marina Dutra-Clarke, Gabriella Horvath, Dana Young, Naama Orenstein, Shahad Bawazeer, Anneke T. Vulto-van Silfhout, Yvan Herenger, Mohammadreza Dehghani, Seyed Mohammad Seyedhassani, Amir Bahreini, Mahya E. Nasab, A. Gulhan Ercan-Sencicek, Zahra Firoozfar, Mojtaba Movahedinia, Stephanie Efthymiou, Pasquale Striano, Ehsan Ghayoor Karimiani, Vincenzo Salpietro, Jenny C. Taylor, Melody Redman, Alexander P.A. Stegmann, Andreas Laner, Ghada Abdel-Salam, Megan Li, Mario Bengala, Amelie Johanna Müller, Maria C. Digilio, Anita Rauch, Murat Gunel, Hannah Titheradge, Daniela N. Schweitzer, Alison Kraus, Irene Valenzuela, Scott D. McLean, Chanika Phornphutkul, Mustafa Salih, Amber Begtrup, Rhonda E. Schnur, Erin Torti, Tobias B. Haack, Carlos E. Prada, Fowzan S. Alkuraya, Henry Houlden, and Reza Maroofian. Biallelic prmt7 pathogenic variants are associated with a recognizable syndromic neurodevelopmental disorder with short stature, obesity, and craniofacial and digital abnormalities. Genetics in Medicine, 25:135-142, Jan 2023. URL: https://doi.org/10.1016/j.gim.2022.09.016, doi:10.1016/j.gim.2022.09.016. This article has 13 citations and is from a highest quality peer-reviewed journal.

3. (halabelian2021structureandfunction pages 8-9): Levon Halabelian and Dalia Barsyte-Lovejoy. Structure and function of protein arginine methyltransferase prmt7. Life, 11:768, Jul 2021. URL: https://doi.org/10.3390/life11080768, doi:10.3390/life11080768. This article has 31 citations.

4. (cali2023biallelicprmt7pathogenic pages 5-6): Elisa Cali, Mohnish Suri, Marcello Scala, Matteo P. Ferla, Shahryar Alavi, Eissa Ali Faqeih, Emilia K. Bijlsma, Kristen M. Wigby, Diana Baralle, Mohammad Y.V. Mehrjardi, Jennifer Schwab, Konrad Platzer, Katharina Steindl, Mais Hashem, Marilyn Jones, Dmitriy M. Niyazov, Jennifer Jacober, Rebecca Okashah Littlejohn, Denisa Weis, Neda Zadeh, Lance Rodan, Alice Goldenberg, François Lecoquierre, Marina Dutra-Clarke, Gabriella Horvath, Dana Young, Naama Orenstein, Shahad Bawazeer, Anneke T. Vulto-van Silfhout, Yvan Herenger, Mohammadreza Dehghani, Seyed Mohammad Seyedhassani, Amir Bahreini, Mahya E. Nasab, A. Gulhan Ercan-Sencicek, Zahra Firoozfar, Mojtaba Movahedinia, Stephanie Efthymiou, Pasquale Striano, Ehsan Ghayoor Karimiani, Vincenzo Salpietro, Jenny C. Taylor, Melody Redman, Alexander P.A. Stegmann, Andreas Laner, Ghada Abdel-Salam, Megan Li, Mario Bengala, Amelie Johanna Müller, Maria C. Digilio, Anita Rauch, Murat Gunel, Hannah Titheradge, Daniela N. Schweitzer, Alison Kraus, Irene Valenzuela, Scott D. McLean, Chanika Phornphutkul, Mustafa Salih, Amber Begtrup, Rhonda E. Schnur, Erin Torti, Tobias B. Haack, Carlos E. Prada, Fowzan S. Alkuraya, Henry Houlden, and Reza Maroofian. Biallelic prmt7 pathogenic variants are associated with a recognizable syndromic neurodevelopmental disorder with short stature, obesity, and craniofacial and digital abnormalities. Genetics in Medicine, 25:135-142, Jan 2023. URL: https://doi.org/10.1016/j.gim.2022.09.016, doi:10.1016/j.gim.2022.09.016. This article has 13 citations and is from a highest quality peer-reviewed journal.

5. (halabelian2021structureandfunction pages 6-8): Levon Halabelian and Dalia Barsyte-Lovejoy. Structure and function of protein arginine methyltransferase prmt7. Life, 11:768, Jul 2021. URL: https://doi.org/10.3390/life11080768, doi:10.3390/life11080768. This article has 31 citations.

6. (halabelian2021structureandfunction pages 5-6): Levon Halabelian and Dalia Barsyte-Lovejoy. Structure and function of protein arginine methyltransferase prmt7. Life, 11:768, Jul 2021. URL: https://doi.org/10.3390/life11080768, doi:10.3390/life11080768. This article has 31 citations.

7. (cali2023biallelicprmt7pathogenic pages 8-8): Elisa Cali, Mohnish Suri, Marcello Scala, Matteo P. Ferla, Shahryar Alavi, Eissa Ali Faqeih, Emilia K. Bijlsma, Kristen M. Wigby, Diana Baralle, Mohammad Y.V. Mehrjardi, Jennifer Schwab, Konrad Platzer, Katharina Steindl, Mais Hashem, Marilyn Jones, Dmitriy M. Niyazov, Jennifer Jacober, Rebecca Okashah Littlejohn, Denisa Weis, Neda Zadeh, Lance Rodan, Alice Goldenberg, François Lecoquierre, Marina Dutra-Clarke, Gabriella Horvath, Dana Young, Naama Orenstein, Shahad Bawazeer, Anneke T. Vulto-van Silfhout, Yvan Herenger, Mohammadreza Dehghani, Seyed Mohammad Seyedhassani, Amir Bahreini, Mahya E. Nasab, A. Gulhan Ercan-Sencicek, Zahra Firoozfar, Mojtaba Movahedinia, Stephanie Efthymiou, Pasquale Striano, Ehsan Ghayoor Karimiani, Vincenzo Salpietro, Jenny C. Taylor, Melody Redman, Alexander P.A. Stegmann, Andreas Laner, Ghada Abdel-Salam, Megan Li, Mario Bengala, Amelie Johanna Müller, Maria C. Digilio, Anita Rauch, Murat Gunel, Hannah Titheradge, Daniela N. Schweitzer, Alison Kraus, Irene Valenzuela, Scott D. McLean, Chanika Phornphutkul, Mustafa Salih, Amber Begtrup, Rhonda E. Schnur, Erin Torti, Tobias B. Haack, Carlos E. Prada, Fowzan S. Alkuraya, Henry Houlden, and Reza Maroofian. Biallelic prmt7 pathogenic variants are associated with a recognizable syndromic neurodevelopmental disorder with short stature, obesity, and craniofacial and digital abnormalities. Genetics in Medicine, 25:135-142, Jan 2023. URL: https://doi.org/10.1016/j.gim.2022.09.016, doi:10.1016/j.gim.2022.09.016. This article has 13 citations and is from a highest quality peer-reviewed journal.

8. (zhang2024prmt7mediatedpten pages 4-7): Yingfei Zhang, Jia Qing, Yang Li, Xin Gao, Dazhuang Lu, Yiyang Wang, Lanxin Gu, Hui Zhang, Zechuan Li, Xu Wang, Yongsheng Zhou, and Ping Zhang. Prmt7 mediated pten activation promotes bone formation in female mice. bioRxiv, Jul 2024. URL: https://doi.org/10.1101/2024.07.31.605998, doi:10.1101/2024.07.31.605998. This article has 0 citations.

9. (cali2023biallelicprmt7pathogenic pages 6-7): Elisa Cali, Mohnish Suri, Marcello Scala, Matteo P. Ferla, Shahryar Alavi, Eissa Ali Faqeih, Emilia K. Bijlsma, Kristen M. Wigby, Diana Baralle, Mohammad Y.V. Mehrjardi, Jennifer Schwab, Konrad Platzer, Katharina Steindl, Mais Hashem, Marilyn Jones, Dmitriy M. Niyazov, Jennifer Jacober, Rebecca Okashah Littlejohn, Denisa Weis, Neda Zadeh, Lance Rodan, Alice Goldenberg, François Lecoquierre, Marina Dutra-Clarke, Gabriella Horvath, Dana Young, Naama Orenstein, Shahad Bawazeer, Anneke T. Vulto-van Silfhout, Yvan Herenger, Mohammadreza Dehghani, Seyed Mohammad Seyedhassani, Amir Bahreini, Mahya E. Nasab, A. Gulhan Ercan-Sencicek, Zahra Firoozfar, Mojtaba Movahedinia, Stephanie Efthymiou, Pasquale Striano, Ehsan Ghayoor Karimiani, Vincenzo Salpietro, Jenny C. Taylor, Melody Redman, Alexander P.A. Stegmann, Andreas Laner, Ghada Abdel-Salam, Megan Li, Mario Bengala, Amelie Johanna Müller, Maria C. Digilio, Anita Rauch, Murat Gunel, Hannah Titheradge, Daniela N. Schweitzer, Alison Kraus, Irene Valenzuela, Scott D. McLean, Chanika Phornphutkul, Mustafa Salih, Amber Begtrup, Rhonda E. Schnur, Erin Torti, Tobias B. Haack, Carlos E. Prada, Fowzan S. Alkuraya, Henry Houlden, and Reza Maroofian. Biallelic prmt7 pathogenic variants are associated with a recognizable syndromic neurodevelopmental disorder with short stature, obesity, and craniofacial and digital abnormalities. Genetics in Medicine, 25:135-142, Jan 2023. URL: https://doi.org/10.1016/j.gim.2022.09.016, doi:10.1016/j.gim.2022.09.016. This article has 13 citations and is from a highest quality peer-reviewed journal.

10. (halabelian2021structureandfunction pages 12-13): Levon Halabelian and Dalia Barsyte-Lovejoy. Structure and function of protein arginine methyltransferase prmt7. Life, 11:768, Jul 2021. URL: https://doi.org/10.3390/life11080768, doi:10.3390/life11080768. This article has 31 citations.

11. (cali2023biallelicprmt7pathogenic pages 7-8): Elisa Cali, Mohnish Suri, Marcello Scala, Matteo P. Ferla, Shahryar Alavi, Eissa Ali Faqeih, Emilia K. Bijlsma, Kristen M. Wigby, Diana Baralle, Mohammad Y.V. Mehrjardi, Jennifer Schwab, Konrad Platzer, Katharina Steindl, Mais Hashem, Marilyn Jones, Dmitriy M. Niyazov, Jennifer Jacober, Rebecca Okashah Littlejohn, Denisa Weis, Neda Zadeh, Lance Rodan, Alice Goldenberg, François Lecoquierre, Marina Dutra-Clarke, Gabriella Horvath, Dana Young, Naama Orenstein, Shahad Bawazeer, Anneke T. Vulto-van Silfhout, Yvan Herenger, Mohammadreza Dehghani, Seyed Mohammad Seyedhassani, Amir Bahreini, Mahya E. Nasab, A. Gulhan Ercan-Sencicek, Zahra Firoozfar, Mojtaba Movahedinia, Stephanie Efthymiou, Pasquale Striano, Ehsan Ghayoor Karimiani, Vincenzo Salpietro, Jenny C. Taylor, Melody Redman, Alexander P.A. Stegmann, Andreas Laner, Ghada Abdel-Salam, Megan Li, Mario Bengala, Amelie Johanna Müller, Maria C. Digilio, Anita Rauch, Murat Gunel, Hannah Titheradge, Daniela N. Schweitzer, Alison Kraus, Irene Valenzuela, Scott D. McLean, Chanika Phornphutkul, Mustafa Salih, Amber Begtrup, Rhonda E. Schnur, Erin Torti, Tobias B. Haack, Carlos E. Prada, Fowzan S. Alkuraya, Henry Houlden, and Reza Maroofian. Biallelic prmt7 pathogenic variants are associated with a recognizable syndromic neurodevelopmental disorder with short stature, obesity, and craniofacial and digital abnormalities. Genetics in Medicine, 25:135-142, Jan 2023. URL: https://doi.org/10.1016/j.gim.2022.09.016, doi:10.1016/j.gim.2022.09.016. This article has 13 citations and is from a highest quality peer-reviewed journal.

Artifacts

• Edison artifact artifact-00